(Q24247924)

1

0 references

J B Court

2

0 references

H Kynaston

3

0 references

Bernadette Coles

5

0 references

Malcolm Mason

Cochrane Database of Systematic Reviews

6

0 references

publication date

21 July 2003

0 references

published in

0 references

cites work

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Factors affecting recurrence and progression in superficial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Adjuvant Intravesicular Pharmacotherapy for Superficial Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

7 January 2021

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

7 January 2021

Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

7 January 2021

4'-Epidoxorubicin versus Mitomycin C Intravesical Chemoprophylaxis of Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003231

7 January 2021